TJP1 and colitis: Treatment with mesalamine significantly upregulated ZO‐1 expression by 3.13‐fold (F = 65.2, p < 0.0001) and increased AMPK content by 2.32‐fold (F = 78.34, p < 0.0001) relative to the colitis group.